Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
10 sept. 2024 07h00 HE
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
10 sept. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
10 sept. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09 sept. 2024 16h16 HE
|
Treos Bio Corp.
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
World-renowned diabetes researcher joins Wendy Novak Diabetes Institute
09 sept. 2024 10h30 HE
|
Norton Healthcare
LOUISVILLE, Ky., Sept. 09, 2024 (GLOBE NEWSWIRE) -- An internationally known researcher is joining Wendy Novak Diabetes Institute, a part of Norton Healthcare and Norton Children’s, with the goal of...
Stereotaxis to Present at Upcoming Investor Conferences
09 sept. 2024 08h40 HE
|
Stereotaxis, Inc.
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David...
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
09 sept. 2024 07h30 HE
|
Cytokinetics, Incorporated
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,...
Superluminal Medicines Closes $120 Million Series A Round
09 sept. 2024 07h00 HE
|
Superluminal Medicines Inc.
Superluminal Medicines, Inc. announced the closing of a $120 million Series A funding round.
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
09 sept. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
08 sept. 2024 19h10 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...